Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 1998

Class I HLA in patients suffering from tuberculosis - population analysis

Anna Dubaniewicz, Zofia Szczerkowska

Med Sci Monit 1998; 4(1): CR122-126 :: ID: 502841

Abstract

The aim of the present study was the analysis of the relation between the incidence of tuberculosis and particular class I HLA among patients of hospitals in Gdańsk, Gdynia and Sopot. 115 patients with active tuberculosis were included in the examination of HLA from A, B, C locus. The diagnosis of tuberculosis was confirmed bacteriologically by the detection of Mycobacterium tuberculosis in sputum cultures. The control group consisted of 100 healthy, unrelated adults. The examination of class I antigens was performed according to microlymphocytotoxic NIH test by Terasaka. χ2 test was used for statistical analysis with the confidence level of p<0.05, with the use of Yates' modification. The relative risk was calculated according to Woolf's method. The significantly increased value of the test for HLA-B62(15) (χ2=4.1; p<0.05; RR=2.85) and HLA-Cw5 (χ2=3.86; p<0.05; RR=6.72) was found in tuberculosis on the basis of our results. However we found significantly decreased values of χ2 test among patients suffering from tuberculosis with relative risk RR<1 for antigens: HLA-A2 (χ2&eguals;6.8; p<0.001), -A10 (χ2=72.45; p<0.0001), -A26 (10) (χ=4.03; p<0.05), -A11 (χ2=4.36; p<0.05), -B40 (χ2=25.4; p<0.0001), -B7 (χ2=4.75; p<0.05), -Cw1 (χ2=4.1; p<0.05). On the basis of these results it was concluded that: 1. In the population of patients suffering from tuberculosis, living in the area of North Poland antigens HLA-62(15) and HLA-Cw5 were found significantly more frequently in comparison with control group of healthy people. 2. In the examined group of patients antigens HLA-A2, -A26(10), -A11, -B7, -B40, -Cw1 were found significantly less frequently in comparison with the control group.

Keywords: Tuberculosis, HLA-C, HLA-B, HLA-A

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750